Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats

Hypertension Research - Clinical and Experimental

Volumn 19, Issue 2, 1996, Pages 75-81

  Wada, Takeo ^a   Inada, Yoshiyuki ^a   Ojima, Mami ^a   Sanada, Tsukasa ^a   Shibouta, Yumiko ^a   Nishikawa, Kohei ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin II receptor antagonist; Candesartan cilexetil; CV 11974; Enalapril; TCV 116

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; BRADYKININ; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; HYPERTENSION; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRESSOR RESPONSE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0030018332     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.75     Document Type: Article

References (36)

1. Sesoko S, Kaneko Y: Cough associated with the use of captopril. Arch Intern Med 1985; 145: 1524.
2. Coulter MD, Edwards IR: Cough associated with captopril and enalapril. Br Med J 1987; 294: 1521-1523.
3. Orfan N, Patterson R, Dykewicz MS: Severe angioedema related to ACE inhibition in patients with a history of idiopathic angioedema. JAMA 1990; 264: 1287-1289.
4. Levens NR, de Gasparo M, Wood JM, Bottari SP: Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharmacol Toxicol 1992; 71: 241-249.
5. Timmermans PBMWM, Carini DJ, Chiu AT, et al: Angiotensin II receptor antagonists: from discovery to antihypertensive drugs. Hypertension 1991; 18 (Suppl III): III136-III142.
6. Kubo K, Kohara Y, Imamiya E, et al: Nonpeptide angiotensin II receptor antagonists: synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993; 36: 2182-2195.
7. Kubo K, Kohara Y, Yoshimura Y, et al: Nonpeptide angiotensin II receptor antagonists: synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993; 36: 2343-2349.
8. Noda M, Shibouta Y, Inada Y, et al: Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide A II antagonist. Biochem Pharmacol 1993; 46: 311-318.
9. Shibouta Y, Inada Y, Ojima M, et al: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl] biphenyl-4-yl) methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
10. Wada T, Inada Y, Shibouta Y, et al: Antihypertensive action of a nonpeptide angiotensin II (AH) antagonist, TCV-116, in various hypertensive rats. J Hypertens 1992; 10 (Suppl 4): S144.
11. Inada Y, Wada T, Shibouta Y, et al: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1-receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl]biphenyl-4-yl)methyl]-1H-benzimidazole- 7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994; 268: 1540-1547.
12. Inada Y, Tanabe M, Kawazoe K, Nishikawa K: Antihypertensive action of a new angiotensin converting enzyme inhibitor, (R)-3-[(S)-1-carboxy-5-(4-piperidyl) pentyl] amino-4-oxo-2,3,4,5-tetrahydro-1, 5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models. Jpn J Pharmacol 1988; 47: 311-322.
13. Haas E, Goldblatt H, Gipson EC, Lewis L: Extraction, purification, and assay of human renin free of angiotensinase. Circ Res 1966; 19: 739-749.
14. Rohrbach MS: [Glycine-1-14C] hippuryl-L-histydylleucine: a substrate for the radiochemical assay of angiotensin converting enzyme. Anal Biochem 1978; 84: 272-276.
15. Inada Y, Tanabe M, Itoh K, Sugihara H, Nishikawa K: Inhibition of angiotensin converting enzyme by (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl] amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid (CV-5975), a non-sulfhydryl compound. Jpn J Pharmacol 1988; 48: 323-330.
16. Pendleton RG, Gessner G, Horner E: Comparative effects of angiotensin II and angiotensin III in rabbit adrenal and aortic tissues. J Pharmacol Exp Ther 1991; 256: 614-620.
17. Yang HYT, Erdös EG, Levin Y: Characterization of a dipeptide hydrolase (kininase II: angiotensin converting enzyme). J Pharmacol Exp Ther 1971; 177: 291-300.
18. Wong PC, Price WA, Relly TM, Duncia JV, Timmermans PBMWM: Antihypertensive mechanism of captopril in renal hypertensive rats: studies with a nonpeptide angiotensin receptor antagonist and an angiotensin II monoclonal antibody. J Pharmacol Exp Ther 1989; 250: 515-522.
19. Wong PC, Price WA, Chiu AT, et al: Hypotensive action of DuP753, an angiotensin II antagonist, in spontaneously hypertensive rats; nonpeptide angiotensin II receptor antagonists: X. Hypertension 1990; 15: 459-468.
20. Hecker M, Bara AT, Busse R: Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium. Eur Heart J 1993; 14 (Suppl I): 161-163
21. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P: Participation of prostaglandins and bradykinin in the effects of angiotensin II and converting enzyme-inhibition on sympathetic neurotransmission in vivo. Acta Physiol Scand 1994; 152: 83-91
22. Brunner HR, Kirshman JD, Sealy JE, Laragh JH: Hypertension of renal origin: evidence for two different mechanisms. Science 1971; 174: 1344-1346.
23. Gavras H, Brunner HR, Vanghan ED, Laragh JH: Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 1972; 180: 1369-1372.
24. Demassieux S, Boucher R, Grise C, Genest J: Purification and characterization of tonin. Can J Biochem 1976; 54: 788-795.
25. Okunishi H, Miyazaki M, Toda N: Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2: 277-284.
26. Dzau VJ: Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-559.
27. Haas E, Lewis L, Koshy TJ, Varde AU, Renerts L, Bagai RC: Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs. Am J Hypertens 1989; 2: 696-707.
28. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
29. Leite R, Salgado MCO: Increased vascular formation of angiotensin II in one-kidney, one clip hyperten-sion. Hypertension 1992; 19: 575-581.
30. Trong HL, Neurath H, Woodbury RG: Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 1987; 84: 364-367.
31. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU: Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest 1982; 69: 25-30.
32. Boucher R, Demassieux S, Garcia R, Genest J: Tonin, angiotensin II system: a review. Circ Res 1977; 41: 11-26.
33. Thibault G, Genest J: Tonin, an esteroprotease from rat submaxillary glands. Biochim Biophys Acta 1981; 660: 23-29.
34. Arakawa K, Maruta H: Ability of kallikrein to generate angiotensin II-like presser substance and a proposed kinin-tensin enzyme system. Nature 1980; 288: 705-706.
35. Meier M, Kwong PC, Fregeau CJ: Cloning of a gene that encodes a new member of the human cytotoxic cell protease. Biochemistry 1990; 29: 4042-4049.
36. Kohara K, Mikami H, Okuda N, Ogihara T: Peripheral vs. central blockade of the renin-angiotensin system in spontaneously hypertensive rats: comparison of novel AT1 receptor antagonist TCV-116 with angiotensin converting enzyme inhibitor delapril. Hypertens Res 1993; 16: 239-246.